TAT 2020: ICOS Receptor Agonist in Head/Neck Squamous Cell Cancer
Posted: Friday, March 20, 2020
Preliminary data from a first-in-human study found that GSK609—an inducible T-cell co-stimulatory (ICOS) receptor agonist—appears to have single-agent activity in PD-1/L1–experienced squamous cell carcinoma of the head and neck. According to Christophe Le Tourneau, MD, PhD, of the Institut Curie and Paris-Saclay University, Paris, and colleagues, GSK609 also had “promising antitumor activity and a manageable safety profile” in combination with pembrolizumab in patients with previously treated, PD-1/L1–naive head and neck squamous cell cancer. These early findings of the INDUCE-1 trial were originally intended to be presented at the European Society for Medical Oncology (ESMO) Targeted Anticancer Therapies (TAT) Congress 2020 in Paris (Abstract 1O).
The expansion cohort included 17 patients with PD-1/L1-experienced disease—receiving GSK609 at 1 mg/kg as monotherapy—and 34 patients with PD-1/L1-naive disease—receiving a combination of GSK609 at 0.3 mg/kg plus pembrolizumab at 200 mg—until disease progression or unacceptable toxicity. Eligible patients had recurrent or metastatic head and neck squamous cell carcinoma, up to five prior lines of therapy, measurable disease, and no active autoimmune disease.
The median patient age in the monotherapy and combination cohorts was 56 and 61, respectively. In the monotherapy cohort, one of eight evaluable patients had a response; in the combination-therapy cohort, 8 of 29 evaluable patients had a response. Treatment-related adverse events in the overall monotherapy (n = 208) and combination-therapy populations (n = 178) were consistent with previous reports. Further clinical testing of this agent is ongoing.
Disclosure: For full disclosures of the study authors, visit www.esmo.org.